Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanxin Suhe Soft Capsules (冠心苏合软胶囊) is an approved traditional Chinese medicine (TCM) formulation developed and manufactured by Tianjin Central Pharmaceutical. It is formulated as a soft capsule containing a mixture of active botanical ingredients, including Styrax (苏合香), Borneol (冰片), Frankincense (乳香), Sandalwood (檀香), and Inula root (土木香). The medication is primarily indicated for the treatment of coronary heart disease and angina pectoris, specifically targeting symptoms of chest tightness and precordial pain caused by cold coagulation, qi stagnation, and obstruction of heart vessels. It is administered orally to promote qi circulation, broaden the chest, and alleviate pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guanxin suhe soft capsules.